Singapore markets closed
Straits Times Index
3,300.00 -4.00 (-0.12%) S&P 500
5,497.07 +10.04 (+0.18%) Dow
38,909.32 +74.46 (+0.19%) Nasdaq
17,891.79 +29.55 (+0.17%) Bitcoin USD
64,819.42 -170.89 (-0.26%) CMC Crypto 200
1,348.63 -34.04 (-2.46%)
JNJ Jan 2025 260.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 03:38PM EDT. Market open.
Loading interactive chart…
- PR Newswire
TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction
Johnson & Johnson (NYSE: JNJ) today announced positive topline results from the pivotal Phase 3 GRAVITI investigational study of TREMFYA® (guselkumab) subcutaneous (SC) induction therapy in adult patients with moderately to severely active Crohn's disease.1 The study met both co-primary endpoints, achieving statistically significant and clinically meaningful outcomes for clinical remission at Week 12 as well as endoscopic response at Week 12. All remaining multiplicity-controlled secondary endpo
- Simply Wall St.
Johnson & Johnson Insiders Sell US$4.8m Of Stock, Possibly Signalling Caution
In the last year, many Johnson & Johnson ( NYSE:JNJ ) insiders sold a substantial stake in the company which may have...
- Zacks
Johnson & Johnson (JNJ) Stock Falls Amid Market Uptick: What Investors Need to Know
In the latest trading session, Johnson & Johnson (JNJ) closed at $145.65, marking a -0.21% move from the previous day.
© 2024 Yahoo. All rights reserved.